Balchem FY26 Q2 net earnings rise 16.6% to $44.6 million; net sales increase 11.2% to $284 million

Human Nutrition and Health net sales grew 10% to $176.9 million, while Animal Nutrition and Health climbed 15% to $64.5 million.

Balchem posted Q2 2026 GAAP net earnings of $44.6 million, up 16.6% year over year, as net sales rose 11.2% to $284 million.

GAAP EPS increased to $1.39 from $1.17 a year earlier; adjusted EPS rose to $1.49 from $1.27.

Adjusted EBITDA climbed 12.6% year over year to $77.9 million; cash from operations was $46.7 million, with free cash flow of $36.2 million.

Balchem extended its senior secured revolving credit facility maturity to , raising borrowing capacity to .